| Authors: |
Salah S; Department of Medical Oncology and Hematology, Princess Margaret Cancer Center, Toronto, Canada. Electronic address: samer.salah@uhn.on.ca., Lee JL; Department of Oncology and Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea., Rozzi A; Medical Oncology Unit, Istituto Neurotraumatologico Italiano (INI), Grottaferrata, Rome, Italy., Kitamura H; Department of Urology, Graduate School of Medicine and Pharmaceutical Sciences for Research, University of Toyama, Toyama, Japan., Matsumoto K; Department of Urology, Kitasato University School of Medicine, Kanagawa, Japan., Vis DJ; Department of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, Netherlands., Srinivas S; Medical Oncology Department, Stanford University Medical Center, Stanford, CA., Morales-Barrera R; Genitourinary, CNS, and Sarcoma Tumor Unit, Vall d' Hebron University Hospital, Vall d' Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain., Carles J; Genitourinary, CNS, and Sarcoma Tumor Unit, Vall d' Hebron University Hospital, Vall d' Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain., Al-Rimawi D; Office of Scientific Affairs and Research, King Hussein Cancer Centre, Amman, Jordan., Lee S; Division of Hematology-Oncology, Department of Medicine, Dankook University Hospital, Dankook University College of Medicine, Cheonan, Korea., Kim KH; Department of Urology, Soonchunhyang University College of Medicine, Cheonan, Chungcheongnam-do, Korea., Izumi K; Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Ishikawa, Japan., Lewin J; Department of Medical Oncology and Hematology, Princess Margaret Cancer Center, Toronto, Canada. |
